Andrew Baum

“One, given AbbVie's strength in market access in managed markets, I'd be curious on the potential future contagion from IRA-mediated price cuts on the Medicare book spilling over onto the commercial book of business.”

“A question on US commercial access for GLP-1 agonists. First, could you share with us how you're thinking about modeling the impact of the IRA in terms of GLP-1 uptake increasing as a result of the co-pay cap?”

“First, on remternetug, on the timelines on clinical trials, potentially this drug could be launched as early as '25 under accelerated approval one year or so post the introduction of Roche subcutaneous.”

“I'm mindful of the dose-dependent interaction of aspirin with Plavix. You have a number of trials ongoing and completed looking at potential drug interactions with Milvexian.”